A fight is brewing over the Medicare drug price negotiation program after the Trump administration proposed to consider an additional form of drugs for price cuts, spurring more legal and policy concerns from the pharmaceutical industry, Bloomberg Law’s Nyah Phengsitthy reports. The proposal would allow the Centers for Medicare & Medicaid Services to select a fixed-dose combination drug for negotiations if the agency determines it does not have a “clinically meaningful difference” compared to its original drug with the same active moiety or ingredient. Publicly traded companies in the space include CVS Health (CVS), Centene (CNC), Cigna (CI), Elevance Health (ELV), Humana (HUM), Molina Healthcare (MOH) and UnitedHealth (UNH).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Pressure continues to mount on health insurers as costs rise, WSJ says
- JPMorgan says too early to conclude other MCOs exposed to same risk as Centene
- Closing Bell Movers: Centene down 24% after pulling 2025 guidance
- Wells says OBBBA incrementally positive for managed care, uncertainty still high
- Wiley appoints Cigna chief digital, analytics officer Katya Andresen to board